Amgen has a pressing need to replace revenues from major drugs facing loss of exclusivity, but the firm remained patient in its pursuit of ChemoCentryx, before agreeing a $3.7bn buyout.
Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal
SEC Filings Show Tactical Negotiations
Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.
